Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma
Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma
复制标题
DOI：
10.1007/s00432-013-1469-2
复制
发表时间：
2013-09-01
影响因子：
3.6
通讯作者：
Tamer, Lulufer
中科院分区：
文献类型：
--
作者：
Ayaz, Lokman;Gorur, Aysegul;Tamer, Lulufer
已经在许多癌症中发现了改变的微小RNA（miRNA）表达，包括肺癌、乳腺癌、前列腺癌、膀胱癌和结肠直肠癌。近年来的研究表明，在多种癌症中也发现了异常的血浆miRNAs。然而，喉鳞状细胞癌（LSCC）中血浆miRNA表达的变化仍不清楚。本研究旨在探讨喉鳞状细胞癌患者血浆miRNAs的变化，采用高通量实时定量聚合酶链反应技术检测了20例LSCC患者和44例健康人血浆中738种miRNAs的表达谱，结果显示17种miRNAs在LSCC患者血浆中的表达水平显著高于对照组（p < 0.05）。9种miRNAs在喉鳞状细胞癌中的表达水平显著下调（p < 0.05）。另外，17种miRNAs仅在喉鳞状细胞癌中表达，其中5种miRNAs（miR-331- 3 p、603、1303、660- 5 p和212- 3 p）是喉鳞状细胞癌特异性表达，在人类受试者的血浆中从未发现过。
Altered microRNA (miRNA) expression has been found in many cancers, including lung, breast, prostate, bladder and colorectal cancer. Many recent studies have demonstrated that aberrant plasma miRNAs were also found in various types of cancers. However, the alteration in plasma miRNA expressions in laryngeal squamous cell carcinoma (LSCC) remains unclear. The present study aimed to investigate the alterations in plasma miRNAs in LSCC.In the present study, the expression profiles of 738 miRNAs in plasma from 20 patients and 44 healthy subjects were evaluated using high-throughput real-time quantitative polymerase chain reaction.Our results demonstrated that expression levels of 17 miRNAs were significantly upregulated in patients with LSCCs when compared to control group (p < 0.05). Expression levels of nine miRNAs were found significantly downregulated in LSCC patients (p < 0.05). In addition, 17 miRNAs were expressed only in LSCC group, and five of these miRNAs (miR-331-3p, 603, 1303, 660-5p and 212-3p) are LSCC specific and never seen before in plasma of any human subject.In conclusion, our study suggests that detecting these LSCC-specific miRNAs in plasma might serve as novel noninvasive biomarkers for LSCC.